Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

March 24, 2015

Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine

March 17, 2015

Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone

March 12, 2015

Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference

March 12, 2015

/C O R R E C T I O N — Relmada Therapeutics, Inc./

March 5, 2015

Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles

March 3, 2015

Relmada Therapeutics to Present at ROTH Capital Partners 27th Annual Growth Stock Conference

February 24, 2015

Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine

February 9, 2015

Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference

February 4, 2015

Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies

January 16, 2015

Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference

«...22 23 242526 27

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top